Brian Rini, MD
Enriched profileChief of Clinical Trials, Vanderbilt-Ingram Cancer Center; Ingram Professor of Medicine, Vanderbilt University Medical Center · Vanderbilt University Medical Center
Brian Rini is Chief of Clinical Trials, Vanderbilt-Ingram Cancer Center; Ingram Professor of Medicine, Vanderbilt University Medical Center at Vanderbilt University Medical Center. OpenAlex indexes 1,331 publications with 78,561 citations (h-index 123); ClinicalTrials.gov lists 20 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 21 Sept 2026
Overview
Updated 14 Oct 2026
Brian I. Rini, MD, is Chief of Clinical Trials, Vanderbilt-Ingram Cancer Center at Vanderbilt University Medical Center / Vanderbilt-Ingram Cancer Center, Nashville, TN. The public record shows 1,331 publications with 78,561 citations (h-index 123), centered on Renal cell carcinoma treatment, Renal and related cancers, Cancer Genomics and Diagnostics. It also documents an investigator role on 20 registered clinical trials, industry payments reported by 36 companies, 1 NIH-funded awards (2025–2026).
- Most recent indexed publication: 2026 · Nature
- Top research focus: Renal cell carcinoma treatment
- 20 registered trials on ClinicalTrials.gov
- Open Payments reporting from 36 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 21 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 573.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Immediate past Chair
FDA Oncologic Drugs Advisory Committee (ODAC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.vumc.org ↗ - Dean
Academy of Kidney Cancer Investigators (AKCI)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →akci.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kidneycancer.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 20 registered studies on ClinicalTrials.gov. The most recent:
- Pilot Study of Casdatifan-Treated Refractory Renal Cell Carcinoma
Sponsor: Vanderbilt-Ingram Cancer Center
- Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Sponsor: Deciphera Pharmaceuticals, LLC
Industry payments
Updated 14 Oct 2026
36 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202515 payments$25,749openpaymentsdata.cms.gov ↗
- Eisai Inc.Program year20255 payments$11,845openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
73.1%Kinase inhibitor23.9%Cabometyx50%Fotivda16%Lenvima14%Inlyta13%Everolimus6%Part D<11 patientsCytochrome P450 17A1 Inhibitor17.8%Abiraterone Acetate100%Part D≥16 patients+ 4 more classes in this area
Metabolism & gastrointestinal
16.5%Corticosteroid14.6%Prednisone100%Part D≥25 patientsSerotonin-3 Receptor Antagonist1.9%Ondansetron Hcl100%Part D≥12 patientsHormonal (systemic)
2.9%l-Thyroxine2.9%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- Tumor Immunology and Microenvironment Research Program
Vanderbilt University Medical Center
FY2026$164,501P30CA068485 - Tumor Immunology and Microenvironment Research Program
Vanderbilt University Medical Center
FY2025$339,812P30CA068485
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.
Nature reviews. Clinical oncology
Review2026 - Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors.
The oncologist
Clinical Trial2026 - Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.
Journal for immunotherapy of cancer
Guideline2026 - Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
CA: a cancer journal for clinicians
Article2026
Most-cited works
by citation count (OpenAlex)Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/cv/brian-rini-md-1
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - X / Twitter
x.com/brian_rini
Mentions by others
where others cite or feature them- Instagram
instagram.com/p/DIwbN6HJ-_U
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Other
medicine.vumc.org/department-directory/Brian-Rini
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.vumc.org ↗ - Other
vicc.org/member/brian-rini
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vicc.org ↗ - YouTube
YouTube: 'The Uromigos, Dr. Brian Rini & Dr. Tom Powles at ASCO 2025 Discussing ADC's in Bladder Cancer'
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
YouTube: 'TOP3 Highlights for #KidneyCancer from #ESMO25 by Dr. Brian Rini'
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - Instagram
Instagram (vumc_cancer, official VICC account): post on Dr. Brian Rini discussing testicular cancer self-exam awareness
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Vicc.org
Official Vanderbilt-Ingram Cancer Center member page confirming title, department, and research program leadership
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗ - Medicine.vumc.org
Official VUMC department directory listing confirming title, credential (FASCO), and office address
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
Editorial & leadership roles
journal and society appointments- Chief of Clinical Trials
Vanderbilt-Ingram Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗ - Ingram Professor of Medicine
Vanderbilt University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗ - Thomas F. Frist
Sr. Chair in Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗ - Co-Leader
Tumor Immunology and Microenvironment Research Program, Vanderbilt-Ingram Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗ - Professor of Medicine (Hematology and Oncology)
Vanderbilt University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
Awards & honors
honors on the public record- FASCO
Fellow of the American Society of Clinical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
Secondary affiliations
appointments beyond the home institution- Member
American Society of Clinical Oncology (ASCO); serves on ASCO Board of Experts and as kidney-cancer specialty editor for CancerProgress.net
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.vumc.org ↗ - Member
Society for Immunotherapy of Cancer (SITC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.vumc.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kidneycancerconsortium.org ↗
Media & interviews
press, podcasts and appearances- Co-host of "The Uromigos" podcast (with Thomas Powles, MD)
covering genitourinary oncology developments
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →guoncologynow.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →guoncologynow.com ↗
- Featured profile interview "Dr. Brian Rini's Perspective on 25 Years of Kidney Cancer Research"
Kidney Cancer Association
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kidneycancer.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Wei Zheng, MD, PhD, MPH
Vanderbilt University Medical Center
William Schaffner, MD
Vanderbilt University Medical Center
Jordan Berlin, MD
Vanderbilt University Medical Center
Julia Lewis, MD
Vanderbilt University Medical Center
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)